NO20031020L - Hydrokloridsalt av 5-[4-2-[2-(N-metyl-N (2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion - Google Patents

Hydrokloridsalt av 5-[4-2-[2-(N-metyl-N (2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion

Info

Publication number
NO20031020L
NO20031020L NO20031020A NO20031020A NO20031020L NO 20031020 L NO20031020 L NO 20031020L NO 20031020 A NO20031020 A NO 20031020A NO 20031020 A NO20031020 A NO 20031020A NO 20031020 L NO20031020 L NO 20031020L
Authority
NO
Norway
Prior art keywords
thiazolidine
dione
pyridyl
ethoxy
benzyl
Prior art date
Application number
NO20031020A
Other languages
English (en)
Other versions
NO324020B1 (no
NO20031020D0 (no
Inventor
Andrew Simon Craig
Michael John Millan
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20031020D0 publication Critical patent/NO20031020D0/no
Publication of NO20031020L publication Critical patent/NO20031020L/no
Publication of NO324020B1 publication Critical patent/NO324020B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20031020A 2000-09-06 2003-03-05 Hydrokloridsalt av 5-[4-[2-(N-metyl-N (2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion, farmasoytisk sammensetning som innbefatter dette samt fremgangsmate for fremstilling og anvendelse derav NO324020B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021865.1A GB0021865D0 (en) 2000-09-06 2000-09-06 Novel pharmaceutical
PCT/GB2001/003991 WO2002020519A1 (en) 2000-09-06 2001-09-05 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (3)

Publication Number Publication Date
NO20031020D0 NO20031020D0 (no) 2003-03-05
NO20031020L true NO20031020L (no) 2003-05-06
NO324020B1 NO324020B1 (no) 2007-07-30

Family

ID=9898953

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031020A NO324020B1 (no) 2000-09-06 2003-03-05 Hydrokloridsalt av 5-[4-[2-(N-metyl-N (2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion, farmasoytisk sammensetning som innbefatter dette samt fremgangsmate for fremstilling og anvendelse derav

Country Status (34)

Country Link
US (3) US20040034066A1 (no)
EP (1) EP1315723B1 (no)
JP (1) JP2004508369A (no)
KR (1) KR100770513B1 (no)
CN (1) CN100558717C (no)
AP (1) AP1715A (no)
AT (1) ATE300538T1 (no)
AU (2) AU8428401A (no)
BG (1) BG107607A (no)
BR (1) BR0113713A (no)
CA (1) CA2421213A1 (no)
CY (1) CY1105252T1 (no)
CZ (1) CZ302125B6 (no)
DE (1) DE60112310T2 (no)
DK (1) DK1315723T3 (no)
DZ (1) DZ3475A1 (no)
EA (1) EA004296B1 (no)
EC (1) ECSP034505A (no)
ES (1) ES2244647T3 (no)
GB (1) GB0021865D0 (no)
HU (1) HUP0300938A3 (no)
IL (2) IL154724A0 (no)
MA (1) MA25908A1 (no)
MX (1) MXPA03001956A (no)
NO (1) NO324020B1 (no)
NZ (1) NZ524548A (no)
OA (1) OA12375A (no)
PL (1) PL360578A1 (no)
PT (1) PT1315723E (no)
SI (1) SI1315723T1 (no)
SK (1) SK2632003A3 (no)
UA (1) UA74003C2 (no)
WO (1) WO2002020519A1 (no)
ZA (1) ZA200301809B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
JP5063714B2 (ja) * 2010-01-29 2012-10-31 シャープ株式会社 画像読取装置及び画像形成装置
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
RU2487132C1 (ru) * 2012-07-23 2013-07-10 Общество с ограниченной ответственностью "Метаген" Производные циклических 5-нитропиридин-2-ил-тиоалкенил-4-дитиокарбаматов, обладающие противогрибковой активностью, и их применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
EP0896182B1 (fr) * 1997-07-17 2002-04-10 Interlemo Holding S.A. Système connecteur
CN1183130C (zh) * 1999-09-24 2005-01-05 中国人民解放军军事医学科学院毒物药物研究所 噻唑烷类衍生物及其医药用途
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
NZ524548A (en) 2004-10-29
SK2632003A3 (en) 2003-12-02
ES2244647T3 (es) 2005-12-16
BG107607A (bg) 2003-12-31
AU2001284284B2 (en) 2005-08-04
US20040034066A1 (en) 2004-02-19
WO2002020519A1 (en) 2002-03-14
DE60112310D1 (de) 2005-09-01
AU8428401A (en) 2002-03-22
IL154724A0 (en) 2003-10-31
ZA200301809B (en) 2004-04-19
EP1315723A1 (en) 2003-06-04
EA004296B1 (ru) 2004-02-26
UA74003C2 (en) 2005-10-17
KR100770513B1 (ko) 2007-10-25
ATE300538T1 (de) 2005-08-15
US20070191435A1 (en) 2007-08-16
DK1315723T3 (da) 2005-10-24
AP2003002758A0 (en) 2003-06-30
EA200300345A1 (ru) 2003-08-28
NO324020B1 (no) 2007-07-30
CN1366520A (zh) 2002-08-28
MXPA03001956A (es) 2003-06-24
SI1315723T1 (en) 2005-10-31
CZ302125B6 (cs) 2010-11-03
CZ2003615A3 (cs) 2003-11-12
CN100558717C (zh) 2009-11-11
PT1315723E (pt) 2005-11-30
NO20031020D0 (no) 2003-03-05
BR0113713A (pt) 2004-07-06
KR20030027118A (ko) 2003-04-03
EP1315723B1 (en) 2005-07-27
HUP0300938A3 (en) 2005-04-28
OA12375A (en) 2004-03-19
HUP0300938A2 (hu) 2003-11-28
JP2004508369A (ja) 2004-03-18
DZ3475A1 (fr) 2002-03-14
IL154724A (en) 2009-07-20
MA25908A1 (fr) 2003-10-01
AP1715A (en) 2007-02-28
GB0021865D0 (en) 2000-10-18
HK1057749A1 (en) 2004-04-16
DE60112310T2 (de) 2006-02-09
CA2421213A1 (en) 2002-03-14
ECSP034505A (es) 2003-06-25
PL360578A1 (en) 2004-09-06
US20050282867A1 (en) 2005-12-22
CY1105252T1 (el) 2010-03-03

Similar Documents

Publication Publication Date Title
NO20024307D0 (no) Hydrokloridsalter av 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
NO20015147D0 (no) Polymorf av 5-(4-(2-(N-metyl-N-(2- pyridyl)amino)etoksy)benzyl)tiazolidin-2,4-dion, maleinsyresalt
NO2007005I1 (no) N-(2-klor-6-metylfenyl)-2-[[6-[4-(2-hydroksyetyl)-1-piperazinyl]-2-metyl-4-pyrimidinyl]amino]5-tiazolkarboksamid
AU9123201A (en) Novel polymorphic forms of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione maleate and process for their preparation
NO20031020L (no) Hydrokloridsalt av 5-[4-2-[2-(N-metyl-N (2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
NO995938D0 (no) Blanding omfattende 5-[4-[2-(N-metyl-N-2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
IL188116A0 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione
SI1265893T1 (sl) Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona
NO20025882L (no) 5-(4-(2-(N-metyl-N-(2-pyridyl)amino)etoksy)benzyl)-tiazolidin- 2,4-dion hydriodid som farmasöytisk middel
HRP20030068B1 (en) Tartrate salt of thiazolidinedione derivative
SI1173435T1 (en) Polymorph of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione maleic acid salt
HK1059259A (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
HK1055294A (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees